This Article Full Text (OnlineFirst PDF) All Versions of this Article: 1352458508092811v1 14/8/1061    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Google Scholar Articles by Weinstock-Guttman, B Articles by Ramanathan, M PubMed PubMed Citation Articles by Weinstock-Guttman, B Articles by Ramanathan, M Social Bookmarking                   What's this?

Neuromyelitis optica immunoglobulins as a marker of disease activity and response to therapy in patients with neuromyelitis optica

¹ Baird Multiple Sclerosis Center, State University of New York at Buffalo, Buffalo, NY; Department of Neurology, State University of New York at Buffalo, Buffalo, NY
² Department of Neurology, State University of New York at Buffalo, Buffalo, NY
³ Baird Multiple Sclerosis Center, State University of New York at Buffalo, Buffalo, NY
⁴ Department of Neurology, State University of New York at Buffalo, Buffalo, NY; Department of Pharmaceutical Sciences, State University of New York at Buffalo, Buffalo, NY

^* To whom correspondence should be addressed.

	Abstract

Objective

To determine whether neuromyelitis optica (NMO) immunoglobulin (IgG) antibody status in NMO/Devic’s disease patients followed prospectively is persistent or can change relative to the clinical status and/or response to therapy.

Design

A cross-sectional group of patients with NMO, relapsing extensive longitudinal transverse myelitis (RLETM) or optico-spinal multiple sclerosis (OSMS) were evaluated for the presence of NMO IgG antibodies. Repeated evaluation was made in all NMO/RLETM patients and in a subgroup of OSMS patients.

Setting

Baird Multiple Sclerosis Center, Buffalo, New York, an academic multiple sclerosis center.

Results

Out of a consecutive cohort of 38 patients evaluated for the presence of NMO IgG, 12 had NMO and 26 had OSMS. Five of the 12 NMO/RLETM patients were NMO IgG positive at the time of their initial evaluation. Four of these patients were repeatedly tested for NMO IgG: two of these became negative and two remained positive. One patient who was initially negative became positive during an acute event and again became negative during the stable disease phase following treatment. A positive test result was associated with active disease, whereas a negative NMO IgG result was consistently found in stable, long-term treated patients. None of the OSMS patients were positive for NMO IgG even during acute attacks.

Conclusions

NMO IgG antibodies are associated with active NMO/RLETM. A well-controlled stable disease usually under effective immunosuppressive therapy can transform the NMO IgG to a negative status. Repeated NMO IgG testing should be considered as a useful biological marker for monitoring NMO/RLETM disease and or response to therapy.

Key Words: biomarker, Devic’s disease, monitoring, multiple sclerosis

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?